The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.

ABSTRACT:

Objective

To investigate the prevalence of the MUC5B promoter variant rs35705950 in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and whether its presence predicts response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF).

Methods

SSc-ILD patients who participated in Scleroderma Lung Study (SLS) II (MMF versus CYC) were included in this study (N = 142). TaqMan Genotyping Assays were used to determine the MUC5B rs35705950 single nucleotide polymorphism. Joint models were created to examine how the presence of this variant affected the course of the forced vital capacity (FVC) over 2 years. Linear regression models were used to investigate the relationship between the presence of this variant and the change in quantitative radiogr

SUBMITTER: Volkmann ER 

PROVIDER: S-EPMC7584725 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature